

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7089923

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUZANNE E. WARDELL	05/22/2015
ERIK R. NELSON	05/19/2015
DONALD P. MCDONNELL	05/22/2015
RECEIVING PARTY DATA	
Name:	DUKE UNIVERSITY
Street Address:	2812 ERWIN ROAD
Internal Address:	SUITE 406
City:	DURHAM
State/Country:	NORTH CAROLINA
Postal Code:	27705
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17558731
CORRESPONDENCE DATA	
Fax Number:	(414)277-0656
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(414)271-6560
Email:	dahauser@michaelbest.com
Correspondent Name:	MICHAEL BEST & FRIEDRICH LLP
Address Line 1:	790 N. WATER STREET
Address Line 2:	SUITE 2500
Address Line 4:	MILWAUKEE, WISCONSIN 53202
ATTORNEY DOCKET NUMBER:	028193-9175-US09
NAME OF SUBMITTER:	BERNARD A. BROWN II, PH.D.
SIGNATURE:	/Bernard A. Brown II/
DATE SIGNED:	12/22/2021
Total Attachments: 4	
source=028193-9175-US09_As_Filed_Assignment#page1.tif	
source=028193-9175-US09_As_Filed_Assignment#page2.tif	

source=028193-9175-US09_As_Filed_Assignment#page3.tif

source=028193-9175-US09_As_Filed_Assignment#page4.tif

ASSIGNMENT

Pursuant to our obligation to Duke University (hereinafter referred to as "Assignee"), a North Carolina non-profit institution having its principal place of business at:

2812 Erwin Road
Suite 306
Durham, NC 27705

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged,
we:

Suzanne E. Wardell
28 Arrowhead Court
Durham, NC 27712

Erik R. Nelson
2111 Mullikin Drive
Champaign, IL 61822

Donald P. McDonnell
1002 Gloucester Court
Chapel Hill, NC 27516

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR the specification of which was filed with my authority on March 28, 2015 as International Patent Application No. PCT/US2015/023216 (Atty. File No. 028193-9175-WO00) (hereinafter the "PCT application") which application claims the benefit of United States Provisional Patent Application No. 61/971,627; filed March 28, 2014, United States Provisional Patent Application No. 62/129,379, filed March 6, 2015; and United States Patent Application No. 14/512,061, filed October 10, 2014 (hereinafter the "U.S. provisional patent applications" and the "U.S. patent application");

(2) in and to the PCT application, the U.S. provisional patent applications, and the U.S. patent application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue

applications) based upon said inventions or claiming the benefit of the PCT application, or the U.S. provisional patent applications, or the U.S. patent application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT application, the U.S. provisional patent applications, and the U.S. patent application.

We agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application, the U.S. provisional patent applications, and the U.S. patent application.


We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

5.22.15
Date


Suzanne E. Wardell

22 - May, 2015
Date

Erik R. Nelson

Donald P. McDonnell

ASSIGNMENT

Pursuant to our obligation to Duke University (hereinafter referred to as "Assignee"), a North Carolina non-profit institution having its principal place of business at:

2812 Erwin Road
Suite 306
Durham, NC 27705

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged,

we:

Suzanne E. Wardell
28 Arrowhead Court
Durham, NC 27712

Erik R. Nelson
2111 Mullikin Drive
Champaign, IL 61822

Donald P. McDonnell
1002 Gloucester Court
Chapel Hill, NC 27516

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR the specification of which was filed with my authority on March 28, 2015 as International Patent Application No. PCT/US2015/023216 (Atty. File No. 028193-9175-WO00) (hereinafter the "PCT application") which application claims the benefit of United States Provisional Patent Application No. 61/971,627; filed March 28, 2014, United States Provisional Patent Application No. 62/129,379, filed March 6, 2015; and United States Patent Application No. 14/512,061, filed October 10, 2014 (hereinafter the "U.S. provisional patent applications" and the "U.S. patent application");

(2) in and to the PCT application, the U.S. provisional patent applications, and the U.S. patent application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue

application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT application and the U.S. provisional patent applications.

We agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application and the U.S. provisional patent applications.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.


Date

5-19-15

Date

Date

Suzanne E. Wardell



Erik R. Nelson

Donald P. McDonnell